| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
52,373,000 |
| Market
Cap: |
2.64(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$30.85 - $52.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 474 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Vericel is a biopharmaceutical company providing cell therapies for the sports medicine and severe burn care markets. Co.'s products include: MACI®, which is an autologous cellularized scaffold product indicated for the repair of symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults; and Epicel®, which is a permanent skin replacement for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area. Co. also holds a license for North American rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
134,016 |
288,272 |
298,234 |
338,833 |
| Total Sell Value |
$6,182,554 |
$12,249,320 |
$12,614,520 |
$13,716,779 |
| Total People Sold |
5 |
6 |
7 |
7 |
| Total Sell Transactions |
11 |
28 |
33 |
36 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Zerbe Robert L Md |
officerTitle |
– • – |
2006-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
7,200 |
7,200 |
|
- |
|
| Fingerle Linda M |
officerTitle |
– – – |
2005-12-20 |
4 |
S |
$2.32 |
$48,720 |
D/D |
(21,000) |
6,927 |
|
- |
|
| Wyant Susan |
Director |
– • – |
2005-11-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,900 |
6,900 |
|
- |
|
| Rubino Alan L |
Director |
– • – |
2005-11-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,900 |
6,900 |
|
- |
|
| Sudovar Stephen |
Director |
– • – |
2005-11-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,900 |
6,900 |
|
- |
|
| Mayleben Timothy M |
Director |
– • – |
2005-11-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,900 |
6,900 |
|
- |
|
| Hampson Brian |
VP Product Development |
• – – |
2005-09-20 |
4 |
A |
$0.00 |
$0 |
D/D |
24,000 |
42,673 |
|
- |
|
| Bard Robert |
VP RA/QS |
• – – |
2005-09-20 |
4 |
A |
$0.00 |
$0 |
D/D |
20,100 |
20,100 |
|
- |
|
| Cour James Andrew |
President and COO |
• – – |
2005-09-20 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
45,000 |
|
- |
|
| Armstrong R Douglas Phd |
Chairman and CEO |
• • – |
2005-09-20 |
4 |
A |
$0.00 |
$0 |
D/D |
61,017 |
562,763 |
|
- |
|
| Hock Janet Mary |
VP Global Research |
• – – |
2005-09-20 |
4 |
A |
$0.00 |
$0 |
D/D |
27,400 |
27,400 |
|
- |
|
| Fingerle Linda M |
Director |
– • – |
2005-08-17 |
4 |
B |
$2.79 |
$999 |
D/D |
358 |
7,927 |
2.31 |
- |
|
| Fingerle Linda M |
Director |
– • – |
2005-07-20 |
4 |
B |
$3.12 |
$998 |
D/D |
320 |
7,568 |
2.31 |
- |
|
| Fingerle Linda M |
Director |
– • – |
2005-06-22 |
4 |
B |
$2.82 |
$998 |
D/D |
354 |
7,248 |
2.31 |
- |
|
| Armstrong R Douglas Phd |
Chairman, CEO |
• • – |
2005-05-20 |
4 |
S |
$2.85 |
$344,084 |
D/D |
(120,173) |
501,746 |
|
- |
|
| Fingerle Linda M |
Director |
– • – |
2005-05-18 |
4 |
B |
$2.00 |
$996 |
D/D |
498 |
6,893 |
2.31 |
- |
|
| Armstrong R Douglas Phd |
Chairman, CEO |
• • – |
2005-05-18 |
4 |
S |
$2.25 |
$453,827 |
D/D |
(200,000) |
621,919 |
|
- |
|
| Armstrong R Douglas Phd |
Chairman, CEO |
• • – |
2005-05-17 |
4 |
D |
$2.38 |
$762,012 |
D/D |
(320,173) |
821,919 |
|
- |
|
| Armstrong R Douglas Phd |
Chairman, CEO |
• • – |
2005-05-17 |
4 |
OE |
$0.38 |
$813,713 |
D/D |
821,919 |
1,142,092 |
|
- |
|
| Armstrong R Douglas Phd |
Chairman, CEO |
• • – |
2005-05-17 |
4 |
S |
$2.38 |
$897,067 |
D/D |
(374,106) |
343,610 |
|
- |
|
| Fingerle Linda M |
Director |
– • – |
2005-04-20 |
4 |
B |
$2.23 |
$999 |
D/D |
448 |
6,394 |
2.31 |
- |
|
| Fingerle Linda M |
Director |
– • – |
2005-03-16 |
4 |
B |
$2.64 |
$1,001 |
D/D |
379 |
5,946 |
2.31 |
- |
|
| Hampson Brian |
VP Product Develop |
• – – |
2005-03-03 |
4 |
S |
$2.82 |
$42,300 |
D/D |
(15,000) |
18,673 |
|
- |
|
| Hampson Brian |
VP Product Develop |
• – – |
2005-03-03 |
4 |
OE |
$0.38 |
$5,700 |
D/D |
15,000 |
33,673 |
|
- |
|
| Armstrong R Douglas Phd |
Chairman and CEO |
• • – |
2005-02-23 |
4 |
S |
$2.90 |
$584,056 |
D/D |
(200,000) |
694,279 |
|
- |
|
401 Records found
|
|
Page 15 of 17 |
|
|
1.20 (2.33%) 
